Hypothesis

Targeting the ER‑localized BCL‑2/Beclin‑1 interaction to re‑activate autophagy in senescent cells will shift their secretome from a chronically inflammatory SASP to a transient, tissue‑supportive phenotype without eliminating the cells, thereby preserving their chaperone functions in wound healing and tumor suppression.

Mechanistic Rationale

Senescent cells exhibit a bifurcated SASP: early, beneficial factors that promote repair and later, deleterious cytokines that drive chronic inflammation. The shift is governed by autophagy flux. In aged tissues, NF‑κB up‑regulates anti‑apoptotic BCL‑2 proteins at the ER, which sequester Beclin‑1 away from the Vps34 complex, suppressing autophagy [5][6]. This block leads to accumulation of damaged mitochondria, ROS production, and NLRP3 inflammasome activation, reinforcing a pro‑inflammatory SASP.

Restoring ER‑associated autophagy would lower mitochondrial ROS, reduce inflammasome signaling, and allow the cell to degrade SASP‑regulating cargo such as IL‑1α mRNA and cGAMP, thereby attenuating chronic inflammation while maintaining the secretion of wound‑healing mediators like PDGF‑AA and IL‑6 [1][2]. Importantly, autophagy‑competent senescent cells retain p16^INK4a^‑mediated cell‑cycle arrest, preserving tumor‑suppressive capacity [3].

Thus, pharmacologically disrupting the ER‑BCL‑2/Beclin‑1 interaction (e.g., with a BH3‑mimetic that spares mitochondrial BCL‑2) should convert senescent cells from "chronic inflammatories" to "transient chaperones" without triggering apoptosis.

Testable Predictions

1. Senescent human fibroblasts treated with an ER‑selective BCL‑2 inhibitor will show increased LC3‑II/I ratio and reduced p62 accumulation, indicating restored autophagy.
2. SASP profiling will reveal decreased IL‑1β, IL‑6 (post‑early phase), and CXCL8, while PDGF‑AA and VEGF‑A levels remain unchanged or are modestly elevated compared with untreated senescent cells.
3. In a murine full‑thickness wound model, local delivery of the ER‑BCL‑2/Beclin‑1 disruptor will accelerate closure rates comparable to wild‑type healing, whereas senolytic ablation will delay closure despite lower inflammatory cytokines.
4. Long‑term administration in aged mice will not increase tumorigenesis markers (e.g., Ki‑67, γH2AX) in epithelial compartments, confirming retained tumor suppression.
5. Genetic ablation of Beclin‑1 specifically in senescent cells (using p16‑3MR‑Cre) will abolish the beneficial effects of the ER‑BCL‑2 inhibitor, confirming Beclin‑1 dependence.

Experimental Design

• In vitro: Induce senescence in primary human fibroblasts via irradiation (10 Gy). Treat with ER‑BCL‑2 BH3‑mimetic (e.g., A1331852 derivative tuned for ER retention) or vehicle. Measure autophagy flux (mCherry‑GFP‑LC3), mitochondrial ROS (MitoSOX), inflammasome activation (caspase‑1 p20), and SASP (Luminex).
• In vivo: Use aged (20‑month) C57BL/6 mice with full‑thickness dorsal wounds. Apply hydrogel containing the ER‑selective inhibitor or control senolytic (navitoclax) topically every other day. Monitor wound area histology (H&E, α‑SMA), immunostaining for senescent markers (p16, SA‑β‑gal), and cytokine levels.
• Tumor surveillance: In parallel cohorts, challenge with sub‑carcinogenic DMBA treatment and monitor squamous cell carcinoma incidence over 6 months.
• Controls: Include Beclin‑1 knockout senescent fibroblasts (CRISPR) to verify specificity.

If autophagy restoration re‑programs senescent cells toward a pro‑repair, low‑inflammation state while preserving growth arrest, this hypothesis validates a senomorphic alternative to blanket senolysis, preserving the "chaperone" functions that maintain tissue integrity in aging.